Hello, and welcome to the annual meeting of stakeholders of Sarepta Therapeutics. Please note that today's meeting is being recorded. During the meeting, we'll have a question-and-answer session. You can submit questions or comments at any time by clicking on the message icon. It is now my pleasure to turn today's meeting over to the Chairwoman of the Board, M. Kathleen Barrons, Ph.D. The floor is yours.
Welcome to the 2025 annual meeting of stakeholders for Sarepta Therapeutics. It is now a couple of minutes after 10:00 A.M. Eastern Time, and the meeting will please come to order. My name is Dr. M. Kathleen Barrons, and as Chairwoman of the Board of Directors of Sarepta, I will be presiding over this meeting. Cristin Rothfus, Executive Vice President, Chief General Counsel, and Corporate Secretary, will record the proceedings. Today's meeting will follow the agenda that is attached in the document section of the webcast. If you have questions or comments during the meeting, we ask that you post these questions by clicking on the message icon in the online meeting site. We will conduct the business portion of our meeting first and answer questions at the end of the meeting. Please note only questions that are germane to the purpose of the meeting will be addressed.
Joining me today are the following current members of the Sarepta Board of Directors: Douglas Ingram, Richard Barry, Dr. Kathryn Boer, Michael Chambers, Dr. Stephen Mayo, Dr. Claude Nicaise, Deirdre Connelly, and Dr. Hans Wigzell. Also present today are members of the company's executive committee: Douglas Ingram, President and Chief Executive Officer; Ian Estepan, Executive Vice President, Chief Financial Officer; Bilal Arif, Executive Vice President, Chief Technical Operations Officer; Diane Barry, Executive Vice President, Chief Global Policy and Advocacy Officer; Cristin Rothfus, Executive Vice President, Chief General Counsel, and Corporate Secretary; Dallan Murray, Executive Vice President, Chief Customer Officer; Alison Nasisi, Executive Vice President, Chief People Officer; Louise Rodino-Klapac, Executive Vice President, Head of R&D and Chief Scientific Officer; and Brian Forsa, Vice President, Chief of Staff to the CEO. In addition, Stephen Briggs and Stacy Farese of KPMG, the company's independent registered public accountants, have joined us today.
The Board of Directors has appointed Computershare to serve as Inspector of Elections. Jerry Seiders of Computershare will determine first, the number of shares outstanding; second, the shares represented at the meeting; and third, the validity of the proxies and ballots. Mr. Seiders will also tabulate the votes for this annual meeting. We have a quorum present, which allows us to proceed to the official business of this meeting. We also have an affidavit from Computershare, the company's Inspector of Elections, certifying that the notice of internet availability of proxy materials was mailed and deposited, with the United States Post Office commencing on or about April 24, 2025, to each stockholder of record as of April 8, 2025.
The company has not received notice from any of its stockholders, as required under its bylaws, of any other matters required to be considered at today's meeting, and therefore no proposals may be properly introduced by stockholders. I will now turn to the official business of this meeting. The first matter to be voted upon is Proposal 1: the election of Class 2 Directors on the Board of Sarepta for the two-year term expiring at the 2027 annual general meeting of stockholders and until their successors are duly elected and qualified. The current Board of Directors favors the election of the following individuals: Richard J. Barry, M. Kathleen Barrons, Ph.D., Stephen L. Mayo, Ph.D., and Claude Nicaise, M.D. The second matter to be voted upon is Proposal 2: the advisory vote on the 2024 Named Executive Officer Compensation.
The third matter to be voted upon at this meeting is Proposal 3: to approve an amendment to the company's 2018 Equity Incentive Plan to increase the maximum aggregate number of shares of common stock that may be issued under the plan by 4,300,000 shares to 17,487,596 shares. The fourth matter to be voted upon is Proposal 4: to approve an amendment to the amended and restated 2013 Employee Stock Purchase Plan to increase the number of shares of the company's common stock authorized for issuance under the plan by 300,000 shares to 1,700,000 shares. The fifth matter to be voted upon at this meeting is Proposal 5: the ratification of the selection of KPMG LLP as the independent registered public accounting firm for the company for 2025. We will now proceed to vote on Proposals 1 through 5.
Stockholders who return a proxy card or voted via telephone or internet and do not wish to change their vote do not need to take any further action. If you wish to vote at this meeting and have not yet done so, you may do so now by clicking on the Cast Your Vote button on the web portal and following the instructions there. We will now close the voting polls with respect to the five proposals and the proxy statement. Since the voting polls are now closed, I move that the official business portion of this meeting be concluded. May I have a second?
I second the motion.
I would now ask Mr. Seiders to summarize the tabulation of stockholder votes on the proposals raised at this annual meeting.
Thank you, Dr. Barrons. The preliminary tabulations of the results are as follows: Proposal 1: a preliminary tabulation of the votes received immediately prior to and at this meeting indicate that the director nominees named in the proxy statement, Richard J. Barry, M. Kathleen Barrons, Ph.D., Stephen L. Mayo, Ph.D., and Claude Nicaise, M.D., have been elected to serve for the two-year term expiring at the 2027 annual meeting of stockholders and until his or her successor is duly elected and qualified. Proposal 2: a preliminary tabulation of the votes received immediately prior to and at this meeting indicate that the advisory vote on the 2024 named executive officer compensation has been approved. Proposal 3: a preliminary tabulation of the votes received immediately prior to and at this meeting indicate that the amendment to the company's 2018 equity incentive plan has been approved.
Proposal 4: A preliminary tabulation of the votes received immediately prior to and at this meeting indicate that the amendment to the company's amended and restated 2013 Employee Stock Purchase Plan has been approved. Proposal 5: A preliminary tabulation of the votes received immediately prior to and at this meeting indicate that the selection of KPMG LLP as the independent registered public accounting firm for the company for 2025 has been ratified and approved.
Thank you, Mr. Seiders. At this time, we will take questions from our stockholders. When submitting your questions, please indicate your name, business affiliation, and whether you are a stockholder or a proxy for a stockholder. Please know we will attempt to answer as many questions as time allows, but only questions that are germane to the meeting will be addressed. Thank you all for attending Sarepta's 2025 annual meeting of stockholders. The meeting is now adjourned with respect to all matters. I hope you enjoy the rest of your day.
This concludes the meeting. You may now disconnect. Everyone, have a great day. Hello and welcome to the annual meeting of stockholders of Sarepta Therapeutics. Please note that today's meeting is being recorded. During the meeting, we'll have a question and answer session. You can submit questions or comments at any time by clicking on the message icon. It is now my pleasure to turn today's meeting over to the Chairwoman of the Board, M. Kathleen Barrons, Ph.D. The floor is yours.
Welcome to the 2025 annual meeting of stockholders for Sarepta Therapeutics. It is now a couple of minutes after 10:00 A.M. Eastern Time, and the meeting will please come to order. My name is Dr. M. Kathleen Barrons, and as Chairwoman of the Board of Directors of Sarepta, I will be presiding over this meeting. Kristine Rothfus, Executive Vice President, Chief General Counsel, and Corporate Secretary, will record the proceedings. Today's meeting will follow the agenda that is attached in the document section of the webcast. If you have questions or comments during the meeting, we ask that you post these questions by clicking on the message icon in the online meeting site. We will conduct the business portion of our meeting first and answer questions at the end of the meeting. Please note only questions that are germane to the purpose of the meeting will be addressed.
Joining me today are the following current members of the Sarepta Board of Directors: Douglas Ingram, Richard Barry, Dr. Kathryn Boer, Michael Chambers, Dr. Stephen Mayo, Dr. Claude Nicaise, Deirdre Connelly, and Dr. Hans Wigzell. Also present today are members of the company's executive committee: Douglas Ingram, President and Chief Executive Officer; Ian Estepan, Executive Vice President, Chief Financial Officer; Bilal Arif, Executive Vice President, Chief Technical Operations Officer; Diane Barry, Executive Vice President, Chief Global Policy and Advocacy Officer; Cristin Rothfus, Executive Vice President, Chief General Counsel and Corporate Secretary; Dallan Murray, Executive Vice President, Chief Customer Officer; Alison Nasisi, Executive Vice President, Chief People Officer; Louise Rodino-Klapac, Executive Vice President, Head of R&D and Chief Scientific Officer; and Brian Forsa, Vice President, Chief of Staff to the CEO. In addition, Stephen Briggs and Stacy Farese of KPMG, the company's independent registered public accountants, have joined us today.
The Board of Directors has appointed Computershare to serve as Inspector of Elections. Jerry Seiders of Computershare will determine first, the number of shares outstanding; second, the shares represented at the meeting; and third, the validity of the proxies and ballots. Mr. Seiders will also tabulate the votes for this annual meeting. We have a quorum present, which allows us to proceed to the official business of this meeting. We also have an affidavit from Computershare, the company's Inspector of Elections, certifying that the notice of internet availability of proxy materials was mailed and deposited, with the United States Post Office commencing on or about April 24, 2025, to each stockholder of record as of April 8, 2025.
The company has not received notice from any of its stockholders, as required under its bylaws, of any other matters required to be considered at today's meeting, and therefore no proposals may be properly introduced by stockholders. I will now turn to the official business of this meeting. The first matter to be voted upon is Proposal One: the election of Class 2 Directors on the Board of Sarepta for the two-year term expiring at the 2027 annual general meeting of stockholders and until their successors are duly elected and qualified. The current Board of Directors favors the election of the following individuals: Richard J. Barry, M. Kathleen Barrons, Ph.D., Stephen L. Mayo, Ph.D., and Claude Nicaise, M.D. The second matter to be voted upon is Proposal Two: the advisory vote on the 2024 Named Executive Officer Compensation.
The third matter to be voted upon at this meeting is Proposal Three: to approve an amendment to the company's 2018 Equity Incentive Plan to increase the maximum aggregate number of shares of common stock that may be issued under the plan by 4,300,000 shares to 17,487,596 shares. The fourth matter to be voted upon is Proposal Four: to approve an amendment to the amended and restated 2013 Employee Stock Purchase Plan to increase the number of shares of the company's common stock authorized for issuance under the plan by 300,000 shares to 1,700,000 shares. The fifth matter to be voted upon at this meeting is Proposal Five: the ratification of the selection of KPMG LLP as the independent registered public accounting firm for the company for 2025. We will now proceed to vote on Proposals One through Five.
Stockholders who return a proxy card or voted via telephone or internet and do not wish to change their vote do not need to take any further action. If you wish to vote at this meeting and have not yet done so, you may do so now by clicking on the Cast Your Vote button on the web portal and following the instructions there. We will now close the voting polls with respect to the five proposals and the proxy statements. Since the voting polls are now closed, I move that the official business portion of this meeting be concluded. May I have a second?
I second the motion.
I would now ask Mr. Seiders to summarize the tabulation of stockholder votes on the proposals raised at this annual meeting.
Thank you, Dr. Barrons. The preliminary tabulations of the results are as follows: Proposal One: a preliminary tabulation of the votes received immediately prior to and at this meeting indicate that the director nominees named in the proxy statement, Richard J. Barry, M. Kathleen Barrons, Ph.D., Stephen L. Mayo, Ph.D., and Claude Nicaise, M.D., have been elected to serve for the two-year term expiring at the 2027 annual meeting of stockholders and until his or her successor is duly elected and qualified. Proposal Two: a preliminary tabulation of the votes received immediately prior to and at this meeting indicate that the advisory vote on the 2024 named executive officer compensation has been approved. Proposal Three: a preliminary tabulation of the votes received immediately prior to and at this meeting indicate that the amendment to the company's 2018 Equity Incentive Plan has been approved.
Proposal Four: a preliminary tabulation of the votes received immediately prior to and at this meeting indicate that the amendment to the company's amended and restated 2013 Employee Stock Purchase Plan has been approved. Proposal Five: a preliminary tabulation of the votes received immediately prior to and at this meeting indicate that the selection of KPMG LLP as the independent registered public accounting firm for the company for 2025 has been ratified and approved.
Thank you, Mr. Seiders. At this time, we will take questions from our stockholders. When submitting your questions, please indicate your name, business affiliation, and whether you are a stockholder or a proxy for a stockholder. Please know we will attempt to answer as many questions as time allows, but only questions that are germane to the meeting will be addressed. Thank you all for attending Sarepta's 2025 annual meeting of stockholders. The meeting is now adjourned with respect to all matters. I hope you enjoy the rest of your day.
This concludes the meeting. You may now disconnect. Everyone, have a great day.